Hedge funds and other institutional investors own 16.41% of the company’s stock. Cellectar Biosciences, Inc, a clinical biopharmaceutical company, focuses on the discovery, development ...

Bank of America Corp DE boosted its stake in shares of Cellectar Biosciences, Inc. (NASDAQ:CLRB – Free Report) by 25.3% in the fourth quarter, according to its most recent 13F filing with the ...

On Monday, Oppenheimer reaffirmed its Perform rating for Cellectar Biosciences (NASDAQ:CLRB) shares, a micro-cap biotech currently ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Investing.com – U.S. stocks were mixed after the close on Wednesday, as gains in the Industrials, Telecoms and Oil & Gas sectors... ByInvesting.com • Nov 23, 2016 Cellectar Bio tabs INC ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Blue-chip tech stocks are a big part of President Donald Trump's portfolio, according to his latest financial disclosures.

Reveal insider sentiment with alternative data that tracks buy and sell trades made by top managers and company directors.

At close: April 17 at 4:00:01 PM EDT ...